Veralipride-induced acute coronary syndrome unmasking a non-secreting pheochromocytoma

The administration of veralipride, a centrally acting dopaminergic type 2 (DA2) receptor antagonist, can decrease hot flushes and improve bone density in post-menopausal women (1). Therefore, it entails an alternative to hormone replacement therapy (HRT) in women who have contraindications to estrogen (1). We herein describe the case of a 52-yr-old lady who presented with an acute coronary syndrome shortly after taking veralipride. Based on knowledge that DA2 receptor antagonists trigger catecholamine release (2), a pheochromocytoma was suspected and thereafter diagnosed and excised. Therefore, this is the first case reporting on veralipride unmasking a silent pheochromocytoma.